Zobrazeno 1 - 10
of 243
pro vyhledávání: '"Moon-Jae Chung"'
Autor:
See-Young Lee, Sung-Ill Jang, Moon-Jae Chung, Jae-Hee Cho, Min-Young Do, Hye-Sun Lee, Juyeon Yang, Dong-Ki Lee
Publikováno v:
Journal of Clinical Medicine, Vol 13, Iss 5, p 1186 (2024)
Background: This study evaluated the effectiveness of short fully covered self-expanding metal stents (FCSEMS) with an anti-migration design in treating benign biliary strictures (BBS) not related to living donor liver transplantation (LDLT). Methods
Externí odkaz:
https://doaj.org/article/bd3c4e1dcc8d4f07bcd247ae8c372508
Autor:
Si-Young Kim, Hee-Seung Lee, Seung-Min Bang, Dai-Hoon Han, Ho-Kyoung Hwang, Gi-Hong Choi, Moon-Jae Chung, Seung-Up Kim
Publikováno v:
Cancers, Vol 13, Iss 8, p 1828 (2021)
Dickkopf-related protein 1 (DKK-1) has a diagnostic and prognostic value in various malignant tumors. We investigated the diagnostic and prognostic performance of DKK-1 in combination with carbohydrate antigen 19-9 (CA 19-9) in cholangiocarcinoma (CC
Externí odkaz:
https://doaj.org/article/8eb99386abe3412089e736206dd7bcd7
Autor:
Seung Bae Yoon, Sang Myung Woo, Jung Won Chun, Dong Uk Kim, Jaihwan Kim, Joo Kyung Park, Hoonsub So, Moon Jae Chung, In Rae Cho, Jun Heo
Publikováno v:
Frontiers in Immunology; 2024, p1-13, 13p
Autor:
Chan Su Park, Min Je Sung, So Jeong Kim, Jung Hyun Jo, Hee Seung Lee, Moon Jae Chung, Seungmin Bang, Seung Woo Park, Si Young Song, Jeong Youp Park
Publikováno v:
Cancers, Vol 14, Iss 17, p 4323 (2022)
Some BTC types respond to pembrolizumab, but there are no known prognostic factors to predict its treatment benefits. In this study, we attempted to identify the prognostic factors associated with pembrolizumab as a second-line treatment for gemcitab
Externí odkaz:
https://doaj.org/article/c59fd8e4cdcc4980942f9f0f45f9bde6
Autor:
Galam Leem, Sung-Ill Jang, Jae-Hee Cho, Jung Hyun Jo, Hee Seung Lee, Moon Jae Chung, Jeong Youp Park, Seungmin Bang, Da-Kyung Yoo, Hyo-Cheon Cheon, Jae-Eun Kim, Kyeong-Pill Lim, In-Hye Jung, Jung-Min Im, Yong-Yoon Chung, Seung Woo Park
Publikováno v:
Cancers, Vol 14, Iss 17, p 4229 (2022)
Background and Aim: This study investigated the administration of combination therapy, allogeneic natural killer (NK) cells and pembrolizumab in the treatment of advanced biliary tract cancer to determine the safety and tolerability (phase 1) and the
Externí odkaz:
https://doaj.org/article/f9a3fa4e69b248989d3afc13b9f3e2a8
Autor:
Jung Hyun Jo, Soo Been Park, Joowon Chung, Taeyun Oh, Hee Seung Lee, Moon Jae Chung, Jeong Youp Park, Seungmin Bang, Seung Woo Park, Dawoon E. Jung, Si Young Song
Publikováno v:
BMC Cancer; 3/20/2024, Vol. 24, p1-15, 15p, 6 Graphs
Publikováno v:
Yonsei Medical Journal; Jan2024, Vol. 65 Issue 1, p34-41, 8p
Autor:
Galam Leem, Min Je Sung, Ji Hoon Park, So Jeong Kim, Jung Hyun Jo, Hee Seung Lee, Nam Su Ku, Jeong Youp Park, Seungmin Bang, Seung Woo Park, Si Young Song, Moon Jae Chung
Publikováno v:
American Journal of Gastroenterology (Lippincott Williams & Wilkins); Jan2024, Vol. 119 Issue 1, p183-190, 8p
Autor:
Hee Seung Lee, Jae Seung Lee, Jinyoung Lee, Eun Kyung Kim, Hoguen Kim, Moon Jae Chung, Jeong Youp Park, Seung Woo Park, Si Young Song, Seungmin Bang
Publikováno v:
Cancer Medicine, Vol 8, Iss 7, Pp 3339-3348 (2019)
Abstract Recent studies have identified the mutational landscape of pancreatic cancer and suggested tumor‐specific subtypes. However, the major hurdle against personalized treatment is the difficulty to obtain sufficient cancer tissues from most in
Externí odkaz:
https://doaj.org/article/f04974829024472ab706f15985870543
Autor:
Hee Seung Lee, Wonjeong Chae, Min Je Sung, Jiyoung Keum, Jung Hyun Jo, Moon Jae Chung, Jeong Youp Park, Seung Woo Park, Si Young Song, Eun-Cheol Park, Chung Mo Nam, Sung-In Jang, Seungmin Bang
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 108:1338-1347
Context Considering the absence of methods to find pancreatic cancer early, surveillance of high-risk groups is needed for early diagnosis. Objective The study aimed to investigate the effect in the incidence of pancreatic cancer and the differences